The Global Veterinary Biomarkers Market is projected to expand from USD 1.11 Billion in 2025 to USD 2.31 Billion by 2031, reflecting a compound annual growth rate of 12.99%. Veterinary biomarkers, defined as biological molecules, genes, or specific characteristics, function as indicators of normal biological processes, pathogenic changes, or responses to pharmacological treatments in animals. The market's growth is largely fueled by the increasing incidence of chronic diseases in animals and a growing need for precise, non-invasive diagnostics in fields such as oncology and cardiology. This upward trend is reinforced by the significant rise in the companion animal population, creating a demand for specialized health monitoring solutions. For example, 'FEDIAF' reported in '2024' that '91 million European households owned at least one pet', highlighting the extensive consumer base driving the need for early disease detection capabilities.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 1.11 Billion
Market Size 2031	USD 2.31 Billion
CAGR 2026-2031	12.99%
Fastest Growing Segment	Disease Diagnostics
Largest Market	North America

Despite these positive drivers, the market faces considerable obstacles due to the substantial costs involved in validating and commercializing biomarkers. These high expenses typically result in costly diagnostic tests, which can be financially burdensome for pet owners and smaller veterinary clinics in developing regions. Consequently, these economic factors limit the broad adoption of such diagnostic tools and restrict overall market accessibility.

Market Driver

The marked increase in veterinary healthcare spending serves as a key accelerator for the adoption of sophisticated biomarker solutions. As owners increasingly treat their pets as family members, there is a heightened willingness to pay for premium medical services, including intricate diagnostic tests for chronic ailments such as cardiac disease and cancer. This financial readiness enables veterinary clinics to incorporate expensive biomarker assays into standard practice, elevating them from specialized research instruments to vital clinical resources. Citing the American Pet Products Association's '2024 Dog and Cat Report' from June 2025, total U.S. pet industry spending hit $152 billion in 2024, demonstrating the immense financial backing of this sector. This enhanced purchasing power directly supports the commercial sustainability of new biomarker panels, facilitating broader access to early disease detection for animal owners.

Additionally, technological progress in diagnostic biomarker analysis acts as a secondary major driver, facilitating swift and precise disease profiling at the point of care. Developments in molecular diagnostics and immunoassay platforms have simplified the identification of specific biological markers, permitting veterinarians to implement real-time, evidence-based treatment strategies without total dependence on external labs. This transition is reflected in the financial success of leading companies commercializing these innovations. For example, Idexx Laboratories announced in February 2025, within their 'Fourth Quarter and Full Year 2024 Results', a total revenue of $3.898 billion, fueled by consistent demand for diagnostic tools. Moreover, the market opportunity reaches beyond North America; as noted by UK Pet Food in 2024, 17.2 million UK households owned a pet, establishing a significant European audience for these advanced diagnostic technologies.

Market Challenge

The heavy financial load required for biomarker validation and commercialization acts as a major constraint on the Global Veterinary Biomarkers Market. Producers face high costs during research and regulatory approval stages, forcing them to adopt premium pricing strategies to secure a return on investment. This pricing structure is passed on to the end-user, leading to diagnostic tests that are frequently too costly for standard clinical use. As a result, the uptake of these high-precision tools is hindered, as veterinarians often hesitate to suggest diagnostics that might surpass their clients' financial limits.

Such economic barriers restrict market growth by limiting the use of advanced biomarkers to wealthy pet owners or specialized referral hospitals, preventing them from becoming standard practice in general veterinary care. The market faces difficulty scaling when the intended consumer base is unable to afford these premium prices. Data from the 'American Pet Products Association' indicates that in '2024', 'spending on veterinary care and product sales in the U.S. totaled $39.8 billion'. This level of current spending highlights the substantial financial burden already placed on pet owners, making it difficult to introduce further expensive diagnostic options into the market.

Market Trends

The rise of Veterinary Liquid Biopsy Solutions is revolutionizing the oncology landscape by allowing for the non-invasive identification of circulating tumor nucleosomes and DNA. This development meets a vital market demand for straightforward, accessible screening instruments capable of detecting common cancers like hemangiosarcoma and lymphoma, bypassing the need for complex invasive tissue biopsies. The commercial uptake of these innovative assays is gaining speed as veterinarians incorporate them into standard routines for early disease surveillance. For example, VolitionRx Limited reported in March 2025, within their 'Full Fiscal Year 2024 Financial Results', sales of roughly 120,000 Nu.Q Vet Cancer Tests in 2024, indicating a marked rise in the clinical application of blood-based cancer screening methods.

Concurrently, the growth of Preventive Wellness and Screening Programs is moving the market focus from reactive treatment to proactive health maintenance. Veterinary clinics are increasingly including biomarker panels in standard wellness check-ups for asymptomatic animals, seeking to identify sub-clinical cardiac or renal issues before symptoms appear. This strategic shift is increasing diagnostic usage rates per visit, separate from appointments for illness. Evidence of this rise in proactive testing is seen in recent data; Idexx Laboratories noted in their 'Q2 Fiscal Year 2024 Earnings Call' in August 2024 that diagnostic frequency per wellness visit grew by 100 basis points year-over-year, highlighting the successful incorporation of preventive screening measures into routine veterinary practice.

Key Market Players

Zoetis Inc.
Virbac SA
Life Diagnostics Inc
INGENIUS BIOTECH SL
Merck & Co., Inc.
IDEXX Laboratories, Inc.
Mercodia AB
Antech Diagnostics Inc

Report Scope

In this report, the Global Veterinary Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Biomarkers Market, By Animal Type

Companion Animals
Production Animals

Veterinary Biomarkers Market, By Product Type

Biomarkers
Kits & Reagents
Biomarker Readers

Veterinary Biomarkers Market, By Application

Disease Diagnostics
Preclinical Research
Others

Veterinary Biomarkers Market, By Disease Type

Inflammatory & Infectious Diseases
Cardiovascular Diseases
Skeletal Muscle Diseases
Tumor
Others

Veterinary Biomarkers Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Biomarkers Market.

Available Customizations:

Global Veterinary Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Biomarkers Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Animal Type (Companion Animals, Production Animals)
- 5.2.2. By Product Type (Biomarkers, Kits & Reagents, Biomarker Readers)
- 5.2.3. By Application (Disease Diagnostics, Preclinical Research, Others)
- 5.2.4. By Disease Type (Inflammatory & Infectious Diseases, Cardiovascular Diseases, Skeletal Muscle Diseases, Tumor, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America Veterinary Biomarkers Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Animal Type
- 6.2.2. By Product Type
- 6.2.3. By Application
- 6.2.4. By Disease Type
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Veterinary Biomarkers Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Animal Type
    - 6.3.1.2.2. By Product Type
    - 6.3.1.2.3. By Application
    - 6.3.1.2.4. By Disease Type
- 6.3.2. Canada Veterinary Biomarkers Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Animal Type
    - 6.3.2.2.2. By Product Type
    - 6.3.2.2.3. By Application
    - 6.3.2.2.4. By Disease Type
- 6.3.3. Mexico Veterinary Biomarkers Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Animal Type
    - 6.3.3.2.2. By Product Type
    - 6.3.3.2.3. By Application
    - 6.3.3.2.4. By Disease Type

7. Europe Veterinary Biomarkers Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Animal Type
- 7.2.2. By Product Type
- 7.2.3. By Application
- 7.2.4. By Disease Type
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Veterinary Biomarkers Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Animal Type
    - 7.3.1.2.2. By Product Type
    - 7.3.1.2.3. By Application
    - 7.3.1.2.4. By Disease Type
- 7.3.2. France Veterinary Biomarkers Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Animal Type
    - 7.3.2.2.2. By Product Type
    - 7.3.2.2.3. By Application
    - 7.3.2.2.4. By Disease Type
- 7.3.3. United Kingdom Veterinary Biomarkers Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Animal Type
    - 7.3.3.2.2. By Product Type
    - 7.3.3.2.3. By Application
    - 7.3.3.2.4. By Disease Type
- 7.3.4. Italy Veterinary Biomarkers Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Animal Type
    - 7.3.4.2.2. By Product Type
    - 7.3.4.2.3. By Application
    - 7.3.4.2.4. By Disease Type
- 7.3.5. Spain Veterinary Biomarkers Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Animal Type
    - 7.3.5.2.2. By Product Type
    - 7.3.5.2.3. By Application
    - 7.3.5.2.4. By Disease Type

8. Asia Pacific Veterinary Biomarkers Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Animal Type
- 8.2.2. By Product Type
- 8.2.3. By Application
- 8.2.4. By Disease Type
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Veterinary Biomarkers Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Animal Type
    - 8.3.1.2.2. By Product Type
    - 8.3.1.2.3. By Application
    - 8.3.1.2.4. By Disease Type
- 8.3.2. India Veterinary Biomarkers Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Animal Type
    - 8.3.2.2.2. By Product Type
    - 8.3.2.2.3. By Application
    - 8.3.2.2.4. By Disease Type
- 8.3.3. Japan Veterinary Biomarkers Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Animal Type
    - 8.3.3.2.2. By Product Type
    - 8.3.3.2.3. By Application
    - 8.3.3.2.4. By Disease Type
- 8.3.4. South Korea Veterinary Biomarkers Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Animal Type
    - 8.3.4.2.2. By Product Type
    - 8.3.4.2.3. By Application
    - 8.3.4.2.4. By Disease Type
- 8.3.5. Australia Veterinary Biomarkers Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Animal Type
    - 8.3.5.2.2. By Product Type
    - 8.3.5.2.3. By Application
    - 8.3.5.2.4. By Disease Type

9. Middle East & Africa Veterinary Biomarkers Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Animal Type
- 9.2.2. By Product Type
- 9.2.3. By Application
- 9.2.4. By Disease Type
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Veterinary Biomarkers Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Animal Type
    - 9.3.1.2.2. By Product Type
    - 9.3.1.2.3. By Application
    - 9.3.1.2.4. By Disease Type
- 9.3.2. UAE Veterinary Biomarkers Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Animal Type
    - 9.3.2.2.2. By Product Type
    - 9.3.2.2.3. By Application
    - 9.3.2.2.4. By Disease Type
- 9.3.3. South Africa Veterinary Biomarkers Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Animal Type
    - 9.3.3.2.2. By Product Type
    - 9.3.3.2.3. By Application
    - 9.3.3.2.4. By Disease Type

10. South America Veterinary Biomarkers Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Animal Type
- 10.2.2. By Product Type
- 10.2.3. By Application
- 10.2.4. By Disease Type
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Veterinary Biomarkers Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Animal Type
    - 10.3.1.2.2. By Product Type
    - 10.3.1.2.3. By Application
    - 10.3.1.2.4. By Disease Type
- 10.3.2. Colombia Veterinary Biomarkers Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Animal Type
    - 10.3.2.2.2. By Product Type
    - 10.3.2.2.3. By Application
    - 10.3.2.2.4. By Disease Type
- 10.3.3. Argentina Veterinary Biomarkers Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Animal Type
    - 10.3.3.2.2. By Product Type
    - 10.3.3.2.3. By Application
    - 10.3.3.2.4. By Disease Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Veterinary Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Zoetis Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Virbac SA
15.3. Life Diagnostics Inc
15.4. INGENIUS BIOTECH SL
15.5. Merck & Co., Inc.
15.6. IDEXX Laboratories, Inc.
15.7. Mercodia AB
15.8. Antech Diagnostics Inc

16. Strategic Recommendations

17. About Us & Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION